Société Atossa Genetics Inc Nasdaq
Actions
US04962H2094
Recherche biotechnologique et médicale
Métier
Dirigeants
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Shu-Chih Chen
FOU | Founder | 62 | 01/12/08 |
Steven Quay
CEO | Chief Executive Officer | 73 | 01/12/08 |
Heather Rees
DFI | Director of Finance/CFO | - | 01/01/17 |
Arezoo Mirad
CTO | Chief Tech/Sci/R&D Officer | - | 04/12 |
Richard Graydon
CTO | Chief Tech/Sci/R&D Officer | - | 25/10/22 |
Delly Behen
ADM | Chief Administrative Officer | - | 01/01/14 |
Eric van Zanten
IRC | Investor Relations Contact | - | 07/12/22 |
Administrateurs
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Steven Quay
CEO | Chief Executive Officer | 73 | 01/12/08 |
Director/Board Member | 66 | 01/03/14 | |
H. Remmel
BRD | Director/Board Member | 72 | 01/02/12 |
Shu-Chih Chen
FOU | Founder | 62 | 01/12/08 |
Stephen Galli
BRD | Director/Board Member | 77 | 01/07/11 |
Jonathan Finn
BRD | Director/Board Member | 50 | 08/11 |
Classe d'actions
Vote | Nombre | Flottant | Autocontrôle | Flottant Total | |
---|---|---|---|---|---|
Action A | 1 | 126 624 110 | 125 230 652 ( 98,90 %) | 1 320 046 ( 1,042 %) | 98,90 % |
Action B | 0 | 582 | 0 | 0 |
Coordonnées société
Atossa Therapeutics, Inc.
107 Spring Street
98104, Seattle
+206 588 0256
http://www.atossatherapeutics.comSecteur
Varia. 1 janv. | Capi. | |
---|---|---|
+1,51 % | 42,75 Md | |
+48,49 % | 41,61 Md | |
+8,57 % | 41,34 Md | |
-12,36 % | 26,59 Md | |
+8,92 % | 25,49 Md | |
-25,13 % | 18,12 Md | |
+29,17 % | 12,24 Md | |
-3,12 % | 11,76 Md | |
+6,35 % | 11 Md |